New Guidelines for Severe Community-acquired Pneumonia

Davide Calabretta; Ignacio Martìn-Loeches; Antoni Torres

doi:10.1055/s-0043-1777797

Seminars in Respiratory and Critical Care Medicine, Inhaltsverzeichnis

Semin Respir Crit Care Med 2024; 45(02): 274-286
DOI: 10.1055/s-0043-1777797

Review Article

New Guidelines for Severe Community-acquired Pneumonia

Davide Calabretta

¹Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy

²Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Barcelona, Spain

,

Ignacio Martìn-Loeches

³Department of Intensive Care Medicine, Multidisciplinary Intensive Care Research Organisation (MICRO), St James's Hospital, Dublin, Ireland

⁴Trinity College Dublin, Dublin, Ireland

⁵CIBER of Respiratory Diseases (CIBERES), Institute of Health Carlos III, Madrid, Spain

⁶Department of Pulmonology, Hospital Clínic of Barcelona, Barcelona, Spain

,

Antoni Torres

²Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Barcelona, Spain

⁷Department of Medicine, University of Barcelona, Barcelona, Spain

⁸Centro de Investigación en Red de Enfermedades Respiratorias (CIBERES), Madrid, Spain

› Institutsangaben

Abstract

In 2023, the new European guidelines on severe community-acquired pneumonia, providing clinical practice recommendations for the management of this life-threatening infection, characterized by a high burden of mortality, morbidity, and costs for the society. This review article aims to summarize the principal evidence related to eight different questions covered in the guidelines, by also highlighting the future perspectives for research activity.

Keywords

severe community-acquired pneumonia - acute respiratory failure - empiric antibiotic therapy - viral community-acquired pneumonia - corticosteroid therapy

Volltext

Referenzen

References
1 Torres A, Cilloniz C, Niederman MS. et al. Pneumonia. Nat Rev Dis Primers 2021; 7 (01) 25
2 Martin-Loeches I, Garduno A, Povoa P, Nseir S. Choosing antibiotic therapy for severe community-acquired pneumonia. Curr Opin Infect Dis 2022; 35 (02) 133-139
3 Simonetti AF, Garcia-Vidal C, Viasus D. et al. Declining mortality among hospitalized patients with community-acquired pneumonia. Clin Microbiol Infect 2016; 22 (06) 567.e1-567.e7
4 Kolditz M, Ewig S, Klapdor B. et al; CAPNETZ Study Group. Community-acquired pneumonia as medical emergency: predictors of early deterioration. Thorax 2015; 70 (06) 551-558
5 Cavallazzi R, Furmanek S, Arnold FW. et al. The burden of community-acquired pneumonia requiring admission to ICU in the United States. Chest 2020; 158 (03) 1008-1016
6 Ferrer M, Travierso C, Cilloniz C. et al. Severe community-acquired pneumonia: Characteristics and prognostic factors in ventilated and non-ventilated patients. PLoS ONE 2018; 13 (01) e0191721
7 Morgan AJ, Glossop AJ. Severe community-acquired pneumonia. BJA Educ 2016; 16 (05) 167-172
8 Shoar S, Musher DM. Etiology of community-acquired pneumonia in adults: a systematic review. Pneumonia 2020; 12: 11
9 Rouzé A, Martin-Loeches I, Povoa P. et al; coVAPid Study Group. Relationship between SARS-CoV-2 infection and the incidence of ventilator-associated lower respiratory tract infections: a European multicenter cohort study. Intensive Care Med 2021; 47 (02) 188-198
10 Martin-Loeches I, Torres A, Nagavci B. et al; ERS/ESICM/ESCMID/ALAT guidelines for the management of severe community-acquired pneumonia. Intensive Care Med 2023; 1-18
11 Renaud C, Kollef MH. Classical and molecular techniques to diagnose HAP/VAP. Semin Respir Crit Care Med 2022; 43 (02) 219-228
12 Webb BJ, Jones B, Dean NC. Empiric antibiotic selection and risk prediction of drug-resistant pathogens in community-onset pneumonia. Curr Opin Infect Dis 2016; 29 (02) 167-177
13 Enne VI, Aydin A, Baldan R. et al; INHALE WP1 Study Group. Multicentre evaluation of two multiplex PCR platforms for the rapid microbiological investigation of nosocomial pneumonia in UK ICUs: the INHALE WP1 study. Thorax 2022; 77 (12) 1220-1228
14 Niederman MS, Torres A. Severe community-acquired pneumonia. Eur Respir Rev 2022; 31 (166) 220123
15 Webb BJ, Sorensen J, Mecham I. et al. Antibiotic use and outcomes after implementation of the drug resistance in pneumonia score in ED patients with community-onset pneumonia. Chest 2019; 156 (05) 843-851
16 Jones BE, Ying J, Stevens V. et al. Empirical anti-MRSA vs standard antibiotic therapy and risk of 30-day mortality in patients hospitalized for pneumonia. JAMA Intern Med 2020; 180 (04) 552-560
17 Murphy CN, Fowler R, Balada-Llasat JM. et al. Multicenter evaluation of the BioFire FilmArray Pneumonia/Pneumonia Plus Panel for detection and quantification of agents of lower respiratory tract infection. J Clin Microbiol 2020; 58 (07) e00128-e20
18 Klein M, Bacher J, Barth S. et al. Multicenter evaluation of the Unyvero Platform for testing bronchoalveolar lavage fluid. J Clin Microbiol 2021; 59 (03) e02497-e20
19 Pickens C, Wunderink RG, Qi C. et al. A multiplex polymerase chain reaction assay for antibiotic stewardship in suspected pneumonia. Diagn Microbiol Infect Dis 2020; 98 (04) 115179
20 Brendish NJ, Malachira AK, Armstrong L. et al. Routine molecular point-of-care testing for respiratory viruses in adults presenting to hospital with acute respiratory illness (ResPOC): a pragmatic, open-label, randomised controlled trial. Lancet Respir Med 2017; 5 (05) 401-411
21 Buchan BW, Windham S, Balada-Llasat JM. et al. Practical comparison of the BioFire FilmArray Pneumonia Panel to routine diagnostic methods and potential impact on antimicrobial stewardship in adult hospitalized patients with lower respiratory tract infections. J Clin Microbiol 2020; 58 (07) e00135-e20
22 Charalampous T, Kay GL, Richardson H. et al. Nanopore metagenomics enables rapid clinical diagnosis of bacterial lower respiratory infection. Nat Biotechnol 2019; 37 (07) 783-792
23 Torres A, Lee N, Cilloniz C, Vila J, Van der Eerden M. Laboratory diagnosis of pneumonia in the molecular age. Eur Respir J 2016; 48 (06) 1764-1778
24 Liapikou A, Cillóniz C, Torres A. Emerging strategies for the noninvasive diagnosis of nosocomial pneumonia. Expert Rev Anti Infect Ther 2019; 17 (07) 523-533
25 Risch M, Radjenovic D, Han JN, Wydler M, Nydegger U, Risch L. Comparison of MALDI TOF with conventional identification of clinically relevant bacteria. Swiss Med Wkly 2010; 140: w13095
26 Idelevich EA, Sparbier K, Kostrzewa M, Becker K. Rapid detection of antibiotic resistance by MALDI-TOF mass spectrometry using a novel direct-on-target microdroplet growth assay. Clin Microbiol Infect 2018; 24 (07) 738-743
27 Rybicka M, Miłosz E, Bielawski KP. Superiority of MALDI-TOF mass spectrometry over real-time PCR for SARS-CoV-2 RNA detection. Viruses 2021; 13 (05) 730
28 Mayer LM, Kahlert C, Rassouli F, Vernazza P, Albrich WC. Impact of viral multiplex real-time PCR on management of respiratory tract infection: a retrospective cohort study. Pneumonia 2017; 9 (01) 4
29 Guyatt GH, Alonso-Coello P, Schünemann HJ. et al. Guideline panels should seldom make good practice statements: guidance from the GRADE Working Group. J Clin Epidemiol 2016; 80: 3-7
30 Jones BE, Jones MM, Huttner B. et al. Trends in antibiotic use and nosocomial pathogens in hospitalized veterans with pneumonia at 128 medical centers, 2006-2010. Clin Infect Dis 2015; 61 (09) 1403-1410
31 Jones BE, Brown KA, Jones MM. et al. Variation in empiric coverage versus detection of methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa in hospitalizations for community-onset pneumonia across 128 US Veterans Affairs Medical Centers. Infect Control Hosp Epidemiol 2017; 38 (08) 937-944
32 Aliberti S, Reyes LF, Faverio P. et al; GLIMP investigators. Global initiative for meticillin-resistant Staphylococcus aureus pneumonia (GLIMP): an international, observational cohort study. Lancet Infect Dis 2016; 16 (12) 1364-1376
33 Restrepo MI, Babu BL, Reyes LF. et al; GLIMP. Burden and risk factors for Pseudomonas aeruginosa community-acquired pneumonia: a multinational point prevalence study of hospitalised patients. Eur Respir J 2018; 52 (02) 1701190
34 Villafuerte D, Aliberti S, Soni NJ. et al; GLIMP Investigators. Prevalence and risk factors for Enterobacteriaceae in patients hospitalized with community-acquired pneumonia. Respirology 2020; 25 (05) 543-551
35 Jain S, Self WH, Wunderink RG. et al; CDC EPIC Study Team. Community-acquired pneumonia requiring hospitalization among U.S. Adults. N Engl J Med 2015; 373 (05) 415-427
36 Gil R, Webb BJ. Strategies for prediction of drug-resistant pathogens and empiric antibiotic selection in community-acquired pneumonia. Curr Opin Pulm Med 2020; 26 (03) 249-259
37 Prina E, Ranzani OT, Polverino E. et al. Risk factors associated with potentially antibiotic-resistant pathogens in community-acquired pneumonia. Ann Am Thorac Soc 2015; 12 (02) 153-160
38 Shindo Y, Ito R, Kobayashi D. et al. Risk factors for drug-resistant pathogens in community-acquired and healthcare-associated pneumonia. Am J Respir Crit Care Med 2013; 188 (08) 985-995
39 Shorr AF, Myers DE, Huang DB, Nathanson BH, Emons MF, Kollef MH. A risk score for identifying methicillin-resistant Staphylococcus aureus in patients presenting to the hospital with pneumonia. BMC Infect Dis 2013; 13 (01) 268
40 Aliberti S, Di Pasquale M, Zanaboni AM. et al. Stratifying risk factors for multidrug-resistant pathogens in hospitalized patients coming from the community with pneumonia. Clin Infect Dis 2012; 54 (04) 470-478
41 Niederman MS, Brito V. Pneumonia in the older patient. Clin Chest Med 2007; 28 (04) 751-771
42 Schreiber MP, Chan CM, Shorr AF. Resistant pathogens in nonnosocomial pneumonia and respiratory failure: is it time to refine the definition of health-care-associated pneumonia?. Chest 2010; 137 (06) 1283-1288
43 Webb BJ, Dascomb K, Stenehjem E. et al. Derivation and multicenter validation of the drug resistance in Pneumonia Clinical Prediction Score. Antimicrob Agents Chemother 2016; 60 (05) 2652-2663
44 Maruyama T, Fujisawa T, Ishida T. et al. A therapeutic strategy for all pneumonia patients: a 3-year prospective multicenter cohort study using risk factors for multidrug-resistant pathogens to select initial empiric therapy. Clin Infect Dis 2019; 68 (07) 1080-1088
45 Sando E, Suzuki M, Ishida M. et al. Definitive and indeterminate Pseudomonas aeruginosa infection in adults with community-acquired pneumonia: a prospective observational study. Ann Am Thorac Soc 2021; 18 (09) 1475-1481
46 Torres A, Niederman MS. Too much or too little empiric treatment for Pseudomonas aeruginosa in community-acquired pneumonia?. Ann Am Thorac Soc 2021; 18 (09) 1456-1458
47 Pascual-Guardia S, Amati F., Marin-Corral J. et al Bacterial Patterns and Empiric Antibiotic Use in COPD Patients With Community-Acquired Pneumonia. Archivos de Bronconeumologia 2023; 59 (02) 90-100
48 Tillotson G, Lodise T, Classi P, Mildvan D, McKinnell JA. Antibiotic treatment failure and associated outcomes among adult patients with community-acquired pneumonia in the outpatient setting: a real-world US Insurance Claims Database Study. Open Forum Infect Dis 2020; 7 (03) ofaa065
49 Christ-Crain M, Schuetz P, Müller B. Biomarkers in the management of pneumonia. Expert Rev Respir Med 2008; 2 (05) 565-572
50 Christ-Crain M, Opal SM. Clinical review: the role of biomarkers in the diagnosis and management of community-acquired pneumonia. Crit Care 2010; 14 (01) 203
51 Bouadma L, Luyt CE, Tubach F. et al; PRORATA Trial Group. Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial. Lancet 2010; 375 (9713): 463-474
52 Schuetz P, Wirz Y, Sager R. et al. Effect of procalcitonin-guided antibiotic treatment on mortality in acute respiratory infections: a patient level meta-analysis. Lancet Infect Dis 2018; 18 (01) 95-107
53 Galli F, Bindo F, Motos A. et al Procalcitonin and C-reactive protein to rule out early bacterial coinfection in COVID-19 critically ill patients. Intensive Care Medicine 2023; 49 (08) 934-945
54 Engelmann I, Dubos F, Lobert PE. et al. Diagnosis of viral infections using myxovirus resistance protein A (MxA). Pediatrics 2015; 135 (04) e985-e993
55 Thomas J, Pociute A, Kevalas R, Malinauskas M, Jankauskaite L. Blood biomarkers differentiating viral versus bacterial pneumonia aetiology: a literature review. Ital J Pediatr 2020; 46 (01) 4
56 Mauri T, Turrini C, Eronia N. et al. Physiologic effects of high-flow nasal cannula in acute hypoxemic respiratory failure. Am J Respir Crit Care Med 2017; 195 (09) 1207-1215
57 Lemiale V, Mokart D, Resche-Rigon M. et al; Groupe de Recherche en Réanimation Respiratoire du patient d'Onco-Hématologie (GRRR-OH). Effect of noninvasive ventilation vs oxygen therapy on mortality among immunocompromised patients with acute respiratory failure: a randomized clinical trial. JAMA 2015; 314 (16) 1711-1719
58 Frat JP, Thille AW, Mercat A. et al; FLORALI Study Group, REVA Network. High-flow oxygen through nasal cannula in acute hypoxemic respiratory failure. N Engl J Med 2015; 372 (23) 2185-2196
59 Brambilla AM, Aliberti S, Prina E. et al. Helmet CPAP vs. oxygen therapy in severe hypoxemic respiratory failure due to pneumonia. Intensive Care Med 2014; 40 (07) 942-949
60 Cosentini R, Brambilla AM, Aliberti S. et al. Helmet continuous positive airway pressure vs oxygen therapy to improve oxygenation in community-acquired pneumonia: a randomized, controlled trial. Chest 2010; 138 (01) 114-120
61 Hilbert G, Gruson D, Vargas F. et al. Noninvasive ventilation in immunosuppressed patients with pulmonary infiltrates, fever, and acute respiratory failure. N Engl J Med 2001; 344 (07) 481-487
62 Confalonieri M, Potena A, Carbone G, Porta RD, Tolley EA, Umberto Meduri G. Acute respiratory failure in patients with severe community-acquired pneumonia. Am J Respir Crit Care Med 1999; 160 (05) 1585-1591
63 Patel BK, Wolfe KS, Pohlman AS, Hall JB, Kress JP. Effect of noninvasive ventilation delivered by helmet vs face mask on the rate of endotracheal intubation in patients with acute respiratory distress syndrome: a randomized clinical trial. JAMA 2016; 315 (22) 2435-2441
64 Grieco DL, Menga LS, Raggi V. et al. Physiological comparison of high-flow nasal cannula and helmet noninvasive ventilation in acute hypoxemic respiratory failure. Am J Respir Crit Care Med 2020; 201 (03) 303-312
65 Sim MAB, Dean P, Kinsella J, Black R, Carter R, Hughes M. Performance of oxygen delivery devices when the breathing pattern of respiratory failure is simulated. Anaesthesia 2008; 63 (09) 938-940
66 Sztrymf B, Messika J, Bertrand F. et al. Beneficial effects of humidified high flow nasal oxygen in critical care patients: a prospective pilot study. Intensive Care Med 2011; 37 (11) 1780-1786
67 Riera J, Barbeta E, Tormos A. et al; CIBERESUCICOVID Consortium. Effects of intubation timing in patients with COVID-19 throughout the four waves of the pandemic: a matched analysis. Eur Respir J 2023; 61 (03) 2201426
68 Grasselli G, Calfee CS, Camporota L. et al; European Society of Intensive Care Medicine Taskforce on ARDS. ESICM guidelines on acute respiratory distress syndrome: definition, phenotyping and respiratory support strategies. Intensive Care Med 2023; 49 (07) 727-759
69 Baddour LM, Yu VL, Klugman KP. et al; International Pneumococcal Study Group. Combination antibiotic therapy lowers mortality among severely ill patients with pneumococcal bacteremia. Am J Respir Crit Care Med 2004; 170 (04) 440-444
70 Weiss K, Tillotson GS. The controversy of combination vs monotherapy in the treatment of hospitalized community-acquired pneumonia. Chest 2005; 128 (02) 940-946
71 Hansen MP, Scott AM, McCullough A. et al. Adverse events in people taking macrolide antibiotics versus placebo for any indication. Cochrane Database Syst Rev 2019; 1 (01) CD011825
72 Fish DN. Fluoroquinolone adverse effects and drug interactions. Pharmacotherapy 2001; 21 (10 Pt 2): 253S-272S
73 Altenburg J, de Graaff CS, van der Werf TS, Boersma WG. Immunomodulatory effects of macrolide antibiotics - part 1: biological mechanisms. Respiration 2011; 81 (01) 67-74
74 Martin-Loeches I, Lisboa T, Rodriguez A. et al. Combination antibiotic therapy with macrolides improves survival in intubated patients with community-acquired pneumonia. Intensive Care Med 2010; 36 (04) 612-620
75 Arnold FW, Summersgill JT, Lajoie AS. et al; Community-Acquired Pneumonia Organization (CAPO) Investigators. A worldwide perspective of atypical pathogens in community-acquired pneumonia. Am J Respir Crit Care Med 2007; 175 (10) 1086-1093
76 Mortensen EM, Restrepo MI, Anzueto A, Pugh J. The impact of empiric antimicrobial therapy with a β-lactam and fluoroquinolone on mortality for patients hospitalized with severe pneumonia. Crit Care 2005; 10 (01) R8
77 Wilson BZ, Anzueto A, Restrepo MI, Pugh MJV, Mortensen EM. Comparison of two guideline-concordant antimicrobial combinations in elderly patients hospitalized with severe community-acquired pneumonia. Crit Care Med 2012; 40 (08) 2310-2314
78 Sligl WI, Asadi L, Eurich DT, Tjosvold L, Marrie TJ, Majumdar SR. Macrolides and mortality in critically ill patients with community-acquired pneumonia: a systematic review and meta-analysis. Crit Care Med 2014; 42 (02) 420-432
79 Adrie C, Schwebel C, Garrouste-Orgeas M. et al; Article Was Written on behalf of the Outcomerea Study Group. Initial use of one or two antibiotics for critically ill patients with community-acquired pneumonia: impact on survival and bacterial resistance. Crit Care 2013; 17 (06) R265
80 Ceccato A, Cilloniz C, Ranzani OT. et al. Treatment with macrolides and glucocorticosteroids in severe community-acquired pneumonia: a post-hoc exploratory analysis of a randomized controlled trial. PLoS ONE 2017; 12 (06) e0178022
81 Abbas M, Paul M, Huttner A. New and improved? A review of novel antibiotics for Gram-positive bacteria. Clin Microbiol Infect 2017; 23 (10) 697-703
82 Liapikou A, Cilloniz C, Palomeque A, Torres T. Emerging antibiotics for community-acquired pneumonia. Expert Opin Emerg Drugs 2019; 24 (04) 221-231
83 Eraikhuemen N, Julien D, Kelly A, Lindsay T, Lazaridis D. Treatment of community-acquired pneumonia: a focus on lefamulin. Infect Dis Ther 2021; 10 (01) 149-163
84 Bidell MR, Pai MAP, Lodise TP. Use of oral tetracyclines in the treatment of adult patients with community-acquired bacterial pneumonia: a literature review on the often-overlooked antibiotic class. Antibiotics (Basel) 2020; 9 (12) 905
85 Lupia T, Pallotto C, Corcione S, Boglione L, De Rosa FG. Ceftobiprole perspective: current and potential future indications. Antibiotics (Basel) 2021; 10 (02) 170
86 He H, Wunderink RG. Staphylococcus aureus pneumonia in the community. Semin Respir Crit Care Med 2020; 41 (04) 470-479
87 Torres A, Chalmers JD, Dela Cruz CS. et al. Challenges in severe community-acquired pneumonia: a point-of-view review. Intensive Care Med 2019; 45 (02) 159-171
88 Saura O, Chommeloux J, Levy D, Assouline B, Lefevre L, Luyt CE. Updates in the management of respiratory virus infections in ICU patients: revisiting the non-SARS-CoV-2 pathogens. Expert Rev Anti Infect Ther 2022; 20 (12) 1537-1550
89 Ramirez J, Peyrani P, Wiemken T, Chaves SS, Fry AM. A randomized study evaluating the effectiveness of oseltamivir initiated at the time of hospital admission in adults hospitalized with influenza-associated lower respiratory tract infections. Clin Infect Dis 2018; 67 (05) 736-742
90 Marty FM, Vidal-Puigserver J, Clark C. et al. Intravenous zanamivir or oral oseltamivir for hospitalised patients with influenza: an international, randomised, double-blind, double-dummy, phase 3 trial. Lancet Respir Med 2017; 5 (02) 135-146
91 Dequin PF, Meziani F, Quenot JP. et al; CRICS-TriGGERSep Network. Hydrocortisone in severe community-acquired pneumonia. N Engl J Med 2023; 388 (21) 1931-1941
92 Meduri GU, Shih MC, Bridges L. et al; ESCAPe Study Group. Low-dose methylprednisolone treatment in critically ill patients with severe community-acquired pneumonia. Intensive Care Med 2022; 48 (08) 1009-1023
93 Torres A, Sibila O, Ferrer M. et al. Effect of corticosteroids on treatment failure among hospitalized patients with severe community-acquired pneumonia and high inflammatory response: a randomized clinical trial. JAMA 2015; 313 (07) 677-686
94 Marik P, Kraus P, Sribante J, Havlik I, Lipman J, Johnson DW. Hydrocortisone and tumor necrosis factor in severe community-acquired pneumonia. A randomized controlled study. Chest 1993; 104 (02) 389-392
95 Confalonieri M, Urbino R, Potena A. et al. Hydrocortisone infusion for severe community-acquired pneumonia: a preliminary randomized study. Am J Respir Crit Care Med 2005; 171 (03) 242-248
96 El-Ghamrawy A, Shokeir MH, Esmat AA. Effects of low-dose hydrocortisone in ICU patients with severe community-acquired pneumonia. Egypt J Chest Dis Tuberc 2006; 2006 (55) 91-99
97 Sabry NA, Omar EED. Corticosteroids and ICU course of community acquired pneumonia in Egyptian settings. Pharmacy (Basel) 2011; 2 (02) 73-81
98 Reza Shariatzadeh M, Huang JQ, Marrie TJ. Differences in the features of aspiration pneumonia according to site of acquisition: community or continuing care facility. J Am Geriatr Soc 2006; 54 (02) 296-302
99 Mandell LA, Niederman MS. Aspiration pneumonia. N Engl J Med 2019; 380 (07) 651-663
100 Suzuki J, Ikeda R, Kato K. et al. Characteristics of aspiration pneumonia patients in acute care hospitals: a multicenter, retrospective survey in Northern Japan. PLoS One 2021; 16 (07) e0254261
101 Gupte T, Knack A, Cramer JD. Mortality from aspiration pneumonia: incidence, trends, and risk factors. Dysphagia 2022; 37 (06) 1493-1500
102 Bowerman TJ, Zhang J, Waite LM. Antibacterial treatment of aspiration pneumonia in older people: a systematic review. Clin Interv Aging 2018; 13: 2201-2213
103 Kadowaki M, Demura Y, Mizuno S. et al. Reappraisal of clindamycin IV monotherapy for treatment of mild-to-moderate aspiration pneumonia in elderly patients. Chest 2005; 127 (04) 1276-1282
104 Marumo S, Teranishi T, Higami Y, Koshimo Y, Kiyokawa H, Kato M. Effectiveness of azithromycin in aspiration pneumonia: a prospective observational study. BMC Infect Dis 2014; 14 (01) 685
105 Sun T, Sun L, Wang R. et al. Clinical efficacy and safety of moxifloxacin versus levofloxacin plus metronidazole for community-acquired pneumonia with aspiration factors. Chin Med J (Engl) 2014; 127 (07) 1201-1205
106 Hasegawa S, Shiraishi A, Yaegashi M, Hosokawa N, Morimoto K, Mori T. Ceftriaxone versus ampicillin/sulbactam for the treatment of aspiration-associated pneumonia in adults. J Comp Eff Res 2019; 8 (15) 1275-1284
107 Oi I, Ito I, Tanabe N. et al. Cefepime vs. meropenem for moderate-to-severe pneumonia in patients at risk for aspiration: an open-label, randomized study. J Infect Chemother 2020; 26 (02) 181-187
108 Yoshimatsu Y, Aga M, Komiya K. et al. The clinical significance of anaerobic coverage in the antibiotic treatment of aspiration pneumonia: a systematic review and meta-analysis. J Clin Med 2023; 12 (05) 1992
109 Binz J, Heft M, Robinson S, Jensen H, Newton J. Utilizing procalcitonin in a clinical setting to help differentiate between aspiration pneumonia and aspiration pneumonitis. Diagn Microbiol Infect Dis 2023; 105 (01) 115821